Cargando…
Progress in immunotherapy
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Science China Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023301/ https://www.ncbi.nlm.nih.gov/pubmed/36932314 http://dx.doi.org/10.1007/s11427-023-2322-3 |
| _version_ | 1784908895380045824 |
|---|---|
| author | Sun, Bing Xia, Ningshao Zhang, Xuan |
| author_facet | Sun, Bing Xia, Ningshao Zhang, Xuan |
| author_sort | Sun, Bing |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10023301 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Science China Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100233012023-03-21 Progress in immunotherapy Sun, Bing Xia, Ningshao Zhang, Xuan Sci China Life Sci Editorial Science China Press 2023-03-14 2023 /pmc/articles/PMC10023301/ /pubmed/36932314 http://dx.doi.org/10.1007/s11427-023-2322-3 Text en © Science China Press 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Editorial Sun, Bing Xia, Ningshao Zhang, Xuan Progress in immunotherapy |
| title | Progress in immunotherapy |
| title_full | Progress in immunotherapy |
| title_fullStr | Progress in immunotherapy |
| title_full_unstemmed | Progress in immunotherapy |
| title_short | Progress in immunotherapy |
| title_sort | progress in immunotherapy |
| topic | Editorial |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10023301/ https://www.ncbi.nlm.nih.gov/pubmed/36932314 http://dx.doi.org/10.1007/s11427-023-2322-3 |
| work_keys_str_mv | AT sunbing progressinimmunotherapy AT xianingshao progressinimmunotherapy AT zhangxuan progressinimmunotherapy |